Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer
Imlunestrant has been approved for the treatment of breast cancer. It is a next-generation, brain-penetrant, oral selective estrogen receptor (ER) degrader that provides continuous ER inhibition, including in cancers with mutations in the ESR1 gene encoding ERα.
On December 11, 2024 the results of the EMBER-3 Study were published in The New England Journal of Medicine. The results were presented at SABCS24.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Authors: Komal L. Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O’Shaughnessy, Nadia Harbeck, Lisa A. Carey, Giuseppe Curigliano, Antonio Llombart-Cussac, Elgene Lim, María de la Luz García Tinoco, Joohyuk Sohn, André Mattar, Qingyuan Zhang, Chiun-Sheng Huang, Chih-Chiang Hung, Jorge Luis Martinez Rodriguez, Manuel Ruíz Borrego, Rikiya Nakamura, Kamnesh R. Pradhan, Christoph Cramer von Laue, Emily Barrett, Shanshan Cao, Xuejing Aimee Wang, Lillian M. Smyth, François-Clément Bidard.
Healthcare professionals shared their insights on social media:
“Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (EMBER-3)
Imlunestrant improves PFS in patients with ESR1 mutations. Its combination with abemaciclib extends PFS regardless of ESR1 status.”
“First results from the phase 3 EMBER-3 trial were presented at SABCS24 by Komal Jhaveri New oral SERD imlunestrant delayed progression in metastatic HR+ breast cancers with ESR1 mutations compared to standard treatment and in combo with abemaciclib in all patients.”
“Insightful presentation by Harold J. Burstein on EMBER-3, highlighting key data and its implications for the evolving treatment landscape. With upcoming SERD study readouts, the field is poised for significant advancements in the years ahead.”
“EMBER-3.
Imulen and abema vs Imlun vs SOC ET.
Imlun superior to SOC ET in ESR1m, not in ITT
Imlun and abema vs Imlun, PFS 9.4 vs 5.5 mo, HR 0.57, p<0.0001 (better in ESR1m and without ESR1m), (65% prior cdk4/6i).”
“General session 1 at SABCS24 starts with the very much awaited results of EMBER-3.
3 co-primary endpoints:
- In ESR1-mut patients, imlunestrant increases PFS vs. ET SoC.
- No significant difference in all patients.
- Imlu + abema increases PFS (vs. Imlu) in all pts, regardless of ESR1-mutation.”
“Cowabunga! Riding Breast Cancer’s Biggest Data’s Wave from SABCS24.
EMBER-3 trial: Imlunestrant shows better PFS vs SOC (5.5 vs 3.8) in ER+/HER2- ABC with ESR1 mt. Abemaciclib boosts PFS to 9.4 mo in ITT.
Game-changer? We need ESR1 status?”
“Fantastic discussion of the EMBER-3 trial by Harold J. Burstein with a spot on clinical context!
Benefit of Imlunestrant + abemaciclib observed regardless of ESR1m or PI3Km status, including in the post-CDK 4/6i subgroup.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023